Clinical trials: Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Investigating Clinical Heterogeneity in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Immune checkpoint inhibitors (ICI) can cause immune related adverse events like inflammatory arthritis (ICI-IA). ICI-IA is a new and impactful condition, but there is limited understanding of pathogenesis, natural history, and…
- Trial name
- NCT07737535
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Johns Hopkins University
Inflammatory Arthritis, Immune-related Adverse Event
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
This study will examine the effectiveness of administering adalimumab as a treatment for patients in the early stages of steroid-dependent immune checkpoint Inhibitor associated inflammatory arthritis (ir-IA).
- Trial name
- NCT06037811
- Testing
- Adalimumab, Prednisone
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Tom Appleton